Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue.
Sign Up to like & getrecommendations! Published in 2019 at "Pharmacological research"
DOI: 10.1016/j.phrs.2019.04.009
Abstract: BACKGROUND AND PURPOSE Recombinant human relaxin-2, serelaxin, is being proved as a novel drug with therapeutic efficacy in some cardiovascular diseases, especially heart failure, a disease whose physiopathology and course are firmly correlated with important… read more here.
Keywords: human relaxin; serelaxin; treatment; fatty acids ... See more keywords
Relaxin treatment reduces angiotensin II-induced vasoconstriction in pregnancy and protects against endothelial dysfunction
Sign Up to like & getrecommendations! Published in 2017 at "Biology of Reproduction"
DOI: 10.1093/biolre/iox023
Abstract: ABSTRACT The peptide relaxin has gained considerable attention as a new vasoactive drug, largely through its beneficial therapeutic effects in cardiovascular disease. In this study, we tested the hypothesis that relaxin treatment alleviates systemic vascular… read more here.
Keywords: dysfunction; relaxin treatment; vascular dysfunction; endothelial dysfunction ... See more keywords